Literature DB >> 25065704

Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.

Andrea B Apolo1, Vanessa Hoffman2, Matthew G Kaag3, David M Latini4, Cheryl T Lee5, Jonathan E Rosenberg6, Margaret Knowles7, Dan Theodorescu8, Bogdan A Czerniak9, Jason A Efstathiou10, Matthew L Albert11, Srikala S Sridhar12, Vitaly Margulis13, Surena F Matin14, Matthew D Galsky15, Donna Hansel16, Ashish M Kamat14, Thomas W Flaig8, Angela B Smith17, Edward Messing18, Diane Zipursky Quale2, Yair Lotan19.   

Abstract

OBJECTIVES: The 8th Annual Bladder Cancer Think Tank (BCAN-TT) brought together a multidisciplinary group of clinicians, researchers, and patient advocates in an effort to advance bladder cancer research. METHODS AND MATERIALS: With the theme of "Collaborating to Move Research Forward," the meeting included three panel presentations and seven small working groups.
RESULTS: The panel presentations and interactive discussions focused on three main areas: gender disparities, sexual dysfunction, and targeting novel pathways in bladder cancer. Small working groups also met to identify projects for the upcoming year, including: (1) improving enrollment and quality of clinical trials; (2) collecting data from multiple institutions for future research; (3) evaluating patterns of care for non-muscle-invasive bladder cancer; (4) improving delivery of care for muscle-invasive disease; (5) improving quality of life for survivors; (6) addressing upper tract disease; and (7) examining the impact of health policy changes on research and treatment of bladder cancer.
CONCLUSIONS: The goal of the BCAN-TT is to advance the care of patients with bladder cancer and to promote collaborative research throughout the year. The meeting provided ample opportunities for collaboration among clinicians from multiple disciplines, patients and patient advocates, and industry representatives.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BCAN; Bladder cancer; Gender disparities; Sexual dysfunction; Targeted therapies; Think Tank; Working groups

Mesh:

Year:  2014        PMID: 25065704      PMCID: PMC6776416          DOI: 10.1016/j.urolonc.2014.06.013

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  62 in total

1.  Defecation disturbances after cystectomy for urinary bladder cancer.

Authors:  Helena Thulin; Ulrika Kreicbergs; Erik Onelöv; Christer Ahlstrand; Malcolm Carringer; Sten Holmäng; Börje Ljungberg; Per-Uno Malmström; David Robinsson; Hans Wijkström; N Peter Wiklund; Gunnar Steineck; Lars Henningsohn
Journal:  BJU Int       Date:  2010-11-02       Impact factor: 5.588

2.  APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer.

Authors:  Sei C Sak; Patricia Harnden; Colin F Johnston; Alan B Paul; Anne E Kiltie
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

3.  Androgen regulation of CYP4B1 responsible for mutagenic activation of bladder carcinogens in the rat bladder: detection of CYP4B1 mRNA by competitive reverse transcription-polymerase chain reaction.

Authors:  S Imaoka; Y Yoneda; T Sugimoto; S Ikemoto; T Hiroi; K Yamamoto; T Nakatani; Y Funae
Journal:  Cancer Lett       Date:  2001-05-26       Impact factor: 8.679

4.  Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.

Authors:  Jason A Efstathiou; Daphna Y Spiegel; William U Shipley; Niall M Heney; Donald S Kaufman; Andrzej Niemierko; John J Coen; Rafi Y Skowronski; Jonathan J Paly; Francis J McGovern; Anthony L Zietman
Journal:  Eur Urol       Date:  2011-11-12       Impact factor: 20.096

5.  Unexplained excess risk of bladder cancer in men.

Authors:  P Hartge; E B Harvey; W M Linehan; D T Silverman; J W Sullivan; R N Hoover; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1990-10-17       Impact factor: 13.506

Review 6.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.

Authors:  Marko Babjuk; Willem Oosterlinck; Richard Sylvester; Eero Kaasinen; Andreas Böhle; Juan Palou-Redorta; Morgan Rouprêt
Journal:  Eur Urol       Date:  2011-03-22       Impact factor: 20.096

7.  MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.

Authors:  Ananya Choudhury; Louisa D Nelson; Mark T W Teo; Sameer Chilka; Selina Bhattarai; Colin F Johnston; Faye Elliott; Johanna Lowery; Claire F Taylor; Michael Churchman; Johanne Bentley; Margaret A Knowles; Patricia Harnden; Robert G Bristow; D Timothy Bishop; Anne E Kiltie
Journal:  Cancer Res       Date:  2010-09-15       Impact factor: 12.701

8.  Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia.

Authors:  Sangkyou Lee; Joon Jeong; Tadeusz Majewski; Steven E Scherer; Mi-Sook Kim; Tomasz Tuziak; Kuang S Tang; Keith Baggerly; Herbert Barton Grossman; Jain-Hua Zhou; Lanlan Shen; Jolanta Bondaruk; Saira S Ahmed; Susmita Samanta; Philippe Spiess; Xifeng Wu; Slawomir Filipek; David McConkey; Menashe Bar-Eli; Jean-Pierre Issa; William F Benedict; Bogdan Czerniak
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-16       Impact factor: 11.205

9.  Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival.

Authors:  Tim Lautenschlaeger; Asha George; Alexander C Klimowicz; Jason A Efstathiou; Chin-Lee Wu; Howard Sandler; William U Shipley; William J Tester; Michael P Hagan; Anthony M Magliocco; Arnab Chakravarti
Journal:  Oncologist       Date:  2013-05-31

10.  Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial.

Authors:  Akihiro Ito; Ichiro Shintaku; Makoto Satoh; Naomasa Ioritani; Masataka Aizawa; Tatsuo Tochigi; Sadafumi Kawamura; Hiroshi Aoki; Isao Numata; Atsushi Takeda; Shunichi Namiki; Takashige Namima; Yoshihiro Ikeda; Koichi Kambe; Atsushi Kyan; Seiji Ueno; Kazuhiko Orikasa; Shinnosuke Katoh; Hisanobu Adachi; Satoru Tokuyama; Shigeto Ishidoya; Takuhiro Yamaguchi; Yoichi Arai
Journal:  J Clin Oncol       Date:  2013-03-04       Impact factor: 44.544

View more
  4 in total

1.  Impact of serum vitamin D level on risk of bladder cancer: a systemic review and meta-analysis.

Authors:  Yong Liao; Jian-Lin Huang; Ming-Xing Qiu; Zhi-Wei Ma
Journal:  Tumour Biol       Date:  2014-10-31

2.  Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer.

Authors:  Tracy L Rose; Allison M Deal; Matthew E Nielsen; Angela B Smith; Matthew I Milowsky
Journal:  Cancer       Date:  2016-05-25       Impact factor: 6.860

Review 3.  Bladder cancer in the elderly patient: challenges and solutions.

Authors:  Elizabeth A Guancial; Breton Roussel; Derek P Bergsma; Kevin C Bylund; Deepak Sahasrabudhe; Edward Messing; Supriya G Mohile; Chunkit Fung
Journal:  Clin Interv Aging       Date:  2015-06-10       Impact factor: 4.458

Review 4.  Managing female sexual dysfunction.

Authors:  Sarah S Arthur; Caroline S Dorfman; Lisa A Massa; Rebecca A Shelby
Journal:  Urol Oncol       Date:  2021-07-08       Impact factor: 2.954

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.